Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay
Abstract The ongoing emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants underscores the need for rapid, adaptable, high-throughput testing. However, assays for neutralizing antibodies, which are a good measure of viral protection, usually require cell culture and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | npj Viruses |
| Online Access: | https://doi.org/10.1038/s44298-024-00083-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076648155643904 |
|---|---|
| author | Danielle W. Ali Maggie L. Bartlett Christopher D. Heger Francisco Ramirez Linwood Johnson Kevin L. Schully Eric D. Laing Wei Wang Carol D. Weiss Emilie Goguet Christopher C. Broder Stephanie A. Richard Nusrat J. Epsi Brian Agan David Tribble Mark P. Simons Timothy H. Burgess Edward Mitre Simon Pollett Darci R. Smith |
| author_facet | Danielle W. Ali Maggie L. Bartlett Christopher D. Heger Francisco Ramirez Linwood Johnson Kevin L. Schully Eric D. Laing Wei Wang Carol D. Weiss Emilie Goguet Christopher C. Broder Stephanie A. Richard Nusrat J. Epsi Brian Agan David Tribble Mark P. Simons Timothy H. Burgess Edward Mitre Simon Pollett Darci R. Smith |
| author_sort | Danielle W. Ali |
| collection | DOAJ |
| description | Abstract The ongoing emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants underscores the need for rapid, adaptable, high-throughput testing. However, assays for neutralizing antibodies, which are a good measure of viral protection, usually require cell culture and either infectious SARS-CoV-2 or pseudotyped viral particles. To circumvent the challenges of cell-based assays, SARS-CoV-2 surrogate virus neutralization tests (sVNTs) measure inhibition of the binding of the spike (S) protein receptor binding domain (RBD) to its receptor, human angiotensin-converting enzyme 2 (hACE2) by neutralizing antibodies. Here we tested a prototype automated microfluidic cartridge-based sVNT platform using SARS-CoV-2 wild-type (WT) and B.1.617.2 (Delta) variant RBDs. This sVNT showed a high correlation with cell-based neutralization assays for biospecimens collected post-COVID-19 vaccination and post-SARS-CoV-2 infection as well as for pre-pandemic SARS-CoV-2 negative sera. Thus, this assay, which takes less than 80 min, is a relatively simple, safe, and accurate alternative to traditional VNTs. |
| format | Article |
| id | doaj-art-535cb6844d5b468f9bd2146e1ce2fbeb |
| institution | DOAJ |
| issn | 2948-1767 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Viruses |
| spelling | doaj-art-535cb6844d5b468f9bd2146e1ce2fbeb2025-08-20T02:45:57ZengNature Portfolionpj Viruses2948-17672024-12-01211810.1038/s44298-024-00083-9Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assayDanielle W. Ali0Maggie L. Bartlett1Christopher D. Heger2Francisco Ramirez3Linwood Johnson4Kevin L. Schully5Eric D. Laing6Wei Wang7Carol D. Weiss8Emilie Goguet9Christopher C. Broder10Stephanie A. Richard11Nusrat J. Epsi12Brian Agan13David Tribble14Mark P. Simons15Timothy H. Burgess16Edward Mitre17Simon Pollett18Darci R. Smith19Microbiology and Immunology Department, Biological Defense Research Directorate, Naval Medical Research Command, Fort DetrickMicrobiology and Immunology Department, Biological Defense Research Directorate, Naval Medical Research Command, Fort DetrickProteinSimple, a Bio-Techne brandProteinSimple, a Bio-Techne brandMicrobiology and Immunology Department, Biological Defense Research Directorate, Naval Medical Research Command, Fort DetrickAustere Environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research CommandDepartment of Microbiology and Immunology, Uniformed Services University of the Health SciencesCenter for Biologics Evaluation and Research, U.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research, U.S. Food and Drug AdministrationDepartment of Microbiology and Immunology, Uniformed Services University of the Health SciencesDepartment of Microbiology and Immunology, Uniformed Services University of the Health SciencesHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health SciencesInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health SciencesInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health SciencesInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health SciencesDepartment of Microbiology and Immunology, Uniformed Services University of the Health SciencesHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Microbiology and Immunology Department, Biological Defense Research Directorate, Naval Medical Research Command, Fort DetrickAbstract The ongoing emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants underscores the need for rapid, adaptable, high-throughput testing. However, assays for neutralizing antibodies, which are a good measure of viral protection, usually require cell culture and either infectious SARS-CoV-2 or pseudotyped viral particles. To circumvent the challenges of cell-based assays, SARS-CoV-2 surrogate virus neutralization tests (sVNTs) measure inhibition of the binding of the spike (S) protein receptor binding domain (RBD) to its receptor, human angiotensin-converting enzyme 2 (hACE2) by neutralizing antibodies. Here we tested a prototype automated microfluidic cartridge-based sVNT platform using SARS-CoV-2 wild-type (WT) and B.1.617.2 (Delta) variant RBDs. This sVNT showed a high correlation with cell-based neutralization assays for biospecimens collected post-COVID-19 vaccination and post-SARS-CoV-2 infection as well as for pre-pandemic SARS-CoV-2 negative sera. Thus, this assay, which takes less than 80 min, is a relatively simple, safe, and accurate alternative to traditional VNTs.https://doi.org/10.1038/s44298-024-00083-9 |
| spellingShingle | Danielle W. Ali Maggie L. Bartlett Christopher D. Heger Francisco Ramirez Linwood Johnson Kevin L. Schully Eric D. Laing Wei Wang Carol D. Weiss Emilie Goguet Christopher C. Broder Stephanie A. Richard Nusrat J. Epsi Brian Agan David Tribble Mark P. Simons Timothy H. Burgess Edward Mitre Simon Pollett Darci R. Smith Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay npj Viruses |
| title | Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay |
| title_full | Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay |
| title_fullStr | Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay |
| title_full_unstemmed | Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay |
| title_short | Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay |
| title_sort | automated and virus variant programmable surrogate test qualitatively compares to the gold standard sars cov 2 neutralization assay |
| url | https://doi.org/10.1038/s44298-024-00083-9 |
| work_keys_str_mv | AT daniellewali automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT maggielbartlett automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT christopherdheger automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT franciscoramirez automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT linwoodjohnson automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT kevinlschully automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT ericdlaing automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT weiwang automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT caroldweiss automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT emiliegoguet automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT christophercbroder automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT stephaniearichard automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT nusratjepsi automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT brianagan automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT davidtribble automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT markpsimons automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT timothyhburgess automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT edwardmitre automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT simonpollett automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay AT darcirsmith automatedandvirusvariantprogrammablesurrogatetestqualitativelycomparestothegoldstandardsarscov2neutralizationassay |